3-(4-Fluorobenzyl)-4-methoxybenzaldehyde | 374713-27-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-Fluorobenzyl)-4-methoxybenzaldehyde
• 英文别名: 3-[(4-fluorophenyl)methyl]-4-methoxybenzaldehyde
• CAS: 374713-27-6
• 化学式: C₁₅H₁₃FO₂
• 分子量: 244.265
• InChiKey: YAFDJFVHRRDOQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-Fluorobenzyl)-4-methoxybenzaldehyde 、 1-(3-Bromophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-ol 以 水 为溶剂， 生成 2-(3-bromophenyl)-4-[[3-[(4-fluorophenyl)methyl]-4-methoxyphenyl]methylidene]-5-(trifluoromethyl)pyrazol-3-one
  参考文献：
  名称：

  Development of the next generation of HIV-1 integrase inhibitors: Pyrazolone as a novel inhibitor scaffold

  摘要：

  HIV-1 integrase (IN), one of the essential enzymes in HIV infection, has been validated as a target for HIV treatment. While more than 20 drugs have been approved by the FDA to treat HIV/AIDS, only one drug, Raltegravir (1), was approved as an IN inhibitor. The rapid mutation of the virus, which leads to multidrug resistant HIV strains, presents an urgent need to find potent compounds that can serve as second-generation IN inhibitors. The pyrazolone scaffold, predicted by a computational modeling study using GS-9137(2) as a pharmacophoric model, has shown to inhibit the IN catalytic activities in low micromolar range. We have synthesized various analogs based on the pyrazolone scaffold and performed SAR studies. This paper will showcase the up-to-date result of this scaffold as a promising HIV-1 IN inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.057
• 作为产物：
  描述：

  3-溴-4-甲氧基苯甲醛 、 4-fluorobenzylzinc pivalate 在 [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl) palladium(II) dichloride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以82%的产率得到3-(4-Fluorobenzyl)-4-methoxybenzaldehyde
  参考文献：
  名称：

  [EN] ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME
  [FR] COMPLEXES D'ORGANOZINC ET PROCÉDÉS POUR LEUR FABRICATION ET LEUR UTILISATION

  摘要：

  公开了制备有机锌试剂的方法，包括将（A）有机镁或有机锌配合物与（B）至少一种含有一个或多个羧酸基团和/或醇基团和/或三级胺基团的配位化合物反应，可选地与锌离子和/或锂离子和/或卤离子结合，其中卤离子选自氯离子、溴离子和碘离子，当配位化合物为螯合多胺时，有机锌配合物包括芳基、杂环芳基或苄基，当反应物（A）包含至少一种有机镁配合物时，在存在至少一种配位化合物与锌络合物的情况下进行反应。所得的有机锌试剂可以选择性地从溶剂中分离出来以获得固体试剂。这些试剂可用于通过Negishi交叉偶联反应或通过醛和/或酮氧化加成反应制备有机化合物。有机锌试剂稳定，并且由于其高选择性，允许在交叉偶联过程中保持敏感的官能团，如醛基。

  公开号：

  WO2012085168A1

文献信息

• Diphenylmethane derivatives
  申请人：——

  公开号：US20030203898A1

  公开（公告）日：2003-10-30

  The invention relates to novel diphenylmethane derivatives, processes for their preparation and their use in medicaments, in particular for the indications of arteriosclerosis and hypercholesterolaemia.

  这项发明涉及新型二苯甲烷衍生物，其制备方法以及其在药物中的应用，特别是用于动脉硬化和高胆固醇血症的适应症。
• ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME
  申请人：Knochel Paul

  公开号：US20140031545A1

  公开（公告）日：2014-01-30

  Processes for making an organozinc reagents are disclosed comprising reacting (A) organomagnesium or organozinc complexes with (B) at least one coordination compound comprising one or more carboxylate groups and/or alcoholate groups and/or tertiary amine groups, optionally in combination with zinc ions and/or lithium ions and/or halide ions, wherein the halide ions are selected from chloride, bromide and iodide, the organozinc complex comprises an aryl group, a heteroaryl group or a benzyl group when the coordinating compound is a chelating polyamine, and the reaction is conducted in the presence of zinc complexed with at least one coordinating compound when reactant (A) comprises at least one organomagnesium complex. The resulting organozinc reagents may optionally be isolated from solvents to obtain a solid reagent. The reagents may be used for making organic compounds via Negishi cross-coupling reactions or via aldehyde and/or ketone oxidative addition reactions. The organozinc reagents are stable and, due to their high selectivity, permit maintenance of sensitive functional groups such as aldehydes during cross-coupling.

  公开了制备有机锌试剂的工艺，包括将（A）有机镁或有机锌配合物与（B）至少一种配位化合物反应，该配位化合物包括一个或多个羧酸盐基和/或醇盐基和/或三级胺基，可选地与锌离子和/或锂离子和/或卤素离子组合，其中卤素离子选自氯离子、溴离子和碘离子，当配位化合物为螯合多胺时，有机锌配合物包括苯基、杂环基或苄基，并且当反应物（A）包括至少一个有机镁配合物时，在存在至少一种配位化合物的锌配合物的情况下进行反应。所得有机锌试剂可以选择从溶剂中分离出来以获得固体试剂。该试剂可用于通过Negishi交叉偶联反应或通过醛和/或酮氧化加成反应制备有机化合物。由于其高选择性，有机锌试剂稳定，并允许保持敏感的功能基团，如醛基在交叉偶联反应过程中。
• Organozinc complexes and processes for making and using the same
  申请人：Knochel Paul

  公开号：US09273070B2

  公开（公告）日：2016-03-01

  Processes for making an organozinc reagents are disclosed comprising reacting (A) organomagnesium or organozinc complexes with (B) at least one coordination compound comprising one or more carboxylate groups and/or alcoholate groups and/or tertiary amine groups, optionally in combination with zinc ions and/or lithium ions and/or halide ions, wherein the halide ions are selected from chloride, bromide and iodide, the organozinc complex comprises an aryl group, a heteroaryl group or a benzyl group when the coordinating compound is a chelating polyamine, and the reaction is conducted in the presence of zinc complexed with at least one coordinating compound when reactant (A) comprises at least one organomagnesium complex. The resulting organozinc reagents may optionally be isolated from solvents to obtain a solid reagent. The reagents may be used for making organic compounds via Negishi cross-coupling reactions or via aldehyde and/or ketone oxidative addition reactions. The organozinc reagents are stable and, due to their high selectivity, permit maintenance of sensitive functional groups such as aldehydes during cross-coupling.

  本发明揭示了制备有机锌试剂的方法，包括将（A）有机镁或有机锌配合物与（B）至少一种配位化合物反应，该配位化合物包括一个或多个羧酸基和/或醇基和/或三级胺基，可选择与锌离子和/或锂离子和/或卤化物离子组合使用，其中卤化物离子选自氯化物、溴化物和碘化物，当配位化合物为螯合多胺时，有机锌配合物包括芳基、杂环芳基或苄基，并且当反应物（A）包括至少一个有机镁配合物时，在有机锌试剂生成过程中存在至少一种与锌配位的配位化合物。所得到的有机锌试剂可以选择从溶剂中分离出来以获得固体试剂。这些试剂可以通过Negishi交叉偶联反应或通过醛和/或酮的氧化加成反应制备有机化合物。由于其高选择性，这些有机锌试剂是稳定的，并且允许在交叉偶联反应中维持敏感的功能基团，例如醛基。
• DIPHENYLMETHANDERIVATE
  申请人：Bayer HealthCare AG

  公开号：EP1286957B1

  公开（公告）日：2004-11-03
• US6803480B2
  申请人：——

  公开号：US6803480B2

  公开（公告）日：2004-10-12